Key Highlights

  • Telix Pharmaceuticals (ASX: TLX) traded higher following its Q2 business update.
  • Second-quarter revenue reached approximately USD247 million.
  • First-half revenue totalled around USD477 million.
  • FY2026 revenue guidance of USD950–970 million was reaffirmed.

Telix Pharmaceuticals Limited (ASX: TLX) traded higher during intraday dealings on 21 July 2026 after releasing its second-quarter business update. Investors responded to continued revenue growth, with the company reporting stronger sales across its commercial imaging portfolio while maintaining its full-year revenue guidance. The reported share-price movement reflected intraday trading rather than the official market close.

Radiopharmaceutical Company with Global Reach

Telix Pharmaceuticals is an Australian biopharmaceutical company specialising in radiopharmaceuticals for the diagnosis and treatment of cancer.

The company develops products that combine targeting molecules with radioactive isotopes to identify or treat tumours. Its commercial business is centred on prostate cancer imaging, while its broader pipeline includes programmes targeting kidney cancer, brain cancer and other oncology indications.

Telix is dual listed on the Australian Securities Exchange and Nasdaq under the ticker TLX, with the United States representing its largest commercial market.

Its commercial portfolio is led by Illuccix and Gozellix, while several additional diagnostic and therapeutic candidates continue progressing through regulatory and clinical development.

Revenue Continues to Expand

Telix reported unaudited second-quarter 2026 revenue of approximately USD247 million.

The result represented an increase from approximately USD204 million recorded during the corresponding period of 2025.

Combined with first-quarter revenue of approximately USD230 million, total first-half 2026 revenue reached around USD477 million.

The company also reaffirmed FY2026 revenue guidance of between USD950 million and USD970 million, indicating that current trading remains broadly aligned with management's expectations.

During FY2025, Telix generated revenue of approximately USD803.8 million, representing growth of around 56% compared with the previous year.

The company also reported adjusted EBITDA of approximately USD39.5 million while continuing to invest heavily in research and development, resulting in a loss before income tax of approximately USD5.3 million.

Research and development expenditure reached approximately USD157.1 million during FY2025, reflecting continued investment across multiple clinical programmes.

Commercial Portfolio Continues to Grow

Illuccix remains the company's principal commercial product.

The prostate cancer imaging agent has been launched across more than 20 countries and continues to generate the majority of Telix's commercial revenue.

The company has also expanded its imaging portfolio through Gozellix, another prostate cancer imaging product approved by the US Food and Drug Administration.

Beyond commercial products, Telix continues advancing several pipeline programmes.

These include Zircaix (TLX250-Px), which is being developed for kidney cancer imaging, and Pixclara (TLX101-Px), targeting brain cancer.

The company is also progressing ProstACT Global, a therapeutic programme focused on prostate cancer treatment.

Together, these programmes form the foundation of Telix's longer-term strategy to expand beyond diagnostic imaging into therapeutic radiopharmaceuticals.

Growth Strategy Remains Focused on Pipeline Expansion

Telix continues investing in product development, regulatory submissions and commercial expansion.

For FY2026, the company expects research and development expenditure to range between USD200 million and USD240 million as it advances multiple late-stage clinical programmes.

Management continues targeting growth across both existing commercial products and its broader oncology pipeline.

The latest revenue update suggests commercial momentum has continued into the second half of 2026, although future performance will also depend on regulatory progress, product launches and continued commercial adoption.

What Investors May Watch Next

Investors are likely to monitor future quarterly revenue, regulatory decisions relating to Zircaix and other pipeline assets, commercial performance of Illuccix and Gozellix, research and development progress, and any updates to FY2026 guidance.

Additional product approvals and expansion into new international markets may also remain important.

Risks

Telix Pharmaceuticals remains exposed to regulatory, clinical development and commercial execution risks.

Continued investment in research and development may affect profitability while pipeline programmes remain under development.

The company also faces competition within the radiopharmaceutical industry and relies on successful product approvals, manufacturing capacity and ongoing commercial adoption to support future growth.